<DOC>
	<DOCNO>NCT00336700</DOCNO>
	<brief_summary>Study Hypothesis : To estimate time recurrence pancreatic cancer patient treat adjuvant erlotinib gemcitabine . Combination therapy give 4 month follow single agent erlotinib total 12 month .</brief_summary>
	<brief_title>A Phase II Study Gemcitabine Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer</brief_title>
	<detailed_description>PATIENT POPULATION Resected pancreatic cancer patient ( R0 resection ) within 10 week surgery eligible , provide meet standard eligibility criterion . STUDY DESIGN Phase II , open-label trial erlotinib gemcitabine . SAFETY PLAN Safety assess CTCAE 3.0 STUDY TREATMENT Erlotinib 150 mg/day x 12 month . ( oral ) Gemcitabine 1500 mg/m2 IV 150 minute q 2 week x 4 month Patients monitor serial CT scan first 2 year completion therapy . Clinical Practice : Therapy administer outpatient . Primary Evaluations : Time recurrence CONCOMITANT THERAPY AND CLINICAL PRACTICE No anti-cancer therapy allow study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients potentially resectable pancreatic cancer ( include ampullary cancer ) , prior surgery accrue study . Patients sign consent prior surgery must appropriate diagnostic imaging evaluate one surgical coinvestigators resectable disease , probable pancreatic adenocarcinoma . Patients , sign consent surgery , must adenocarcinoma pancreas negative surgical margin . Adjuvant therapy start within 10 week surgery Age 18 year old ECOG performance status 0 1 ( see Appendix A ) Ability take oral medication without difficulty Adequate bone marrow function evidence absolute neutrophil content ( ANC ) &gt; 1500/mL platelet count &gt; 100,000/mL Adequate renal function evidence serum creatinine within institutional limit creatinine clearance &gt; 50 ml/minute upper institutional limit ( ULN ) Adequate hepatic function evidence ALT total bilirubin within 2 time ULN . Provision write informed consent . Men woman childbearing potential must willing practice acceptable method birth control prevent pregnancy . Positive margin post operative surgical specimen evidence metastatic disease ( positive retroperitoneal margin allow ) Biliary tree cancer allow ( Note : Ampullary cancer allow ) . Known severe hypersensitivity erlotinib excipients product Any prior treatment radiation therapy chemotherapy vaccine pancreatic cancer . Other coexist malignancy malignancy diagnose within last 3 year , exception basal cell carcinoma squamous cell carcinoma skin cervical cancer situ . Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , phenobarbital , St. John 's Wort . Other agent inhibit CYP3A4 may use caution ( Appendix B ) Treatment nonapproved investigational drug prior treatment . Incomplete heal previous oncologic major surgery . Pregnancy breast feeding ( woman childbearing potential ) . As judged investigator , evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) . Evidence significant clinical disorder laboratory find make undesirable subject participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic</keyword>
</DOC>